ERBB2 and neoplasm: VISTA is the first human phase I study to investigate the safety and efficacy of using special immune cells, called HER2 CAR-specific cytotoxic T lymphocytes (HER2-specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system, including HER2-specific CAR T cells, react to the tumor.